Skip to main content

James Crowe Jr.

Vanderbilt leads international effort to develop universal flu vaccine

Oct. 26, 2017—Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world.

Read more


The Human Vaccines Project, Vanderbilt and Illumina join forces to decode the human immunome

Apr. 11, 2017—The Human Vaccines Project and Vanderbilt University Medical Center (VUMC) announced this week that they joined forces with Illumina Inc. to decipher the human immunome, the genetic underpinnings of the immune system.

Read more


Crowe’s pediatric immune response research lauded

Feb. 23, 2017—James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017-2018 recipient of the Samuel Rosenthal Prize for Excellence in Academic Pediatrics.

Read more


Team isolates new antibodies that may aid RSV vaccine design

Feb. 9, 2017—Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.

Read more


Six from Vanderbilt to speak at TEDxNashville March 17–18

Jan. 25, 2017—Astrophysicists, artists, celebrity chefs and clinical psychologists will be among the speakers at the eighth annual TEDxNashville.

Read more


Early study finds antibody that ‘neutralizes’ Zika virus

Nov. 7, 2016—Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.

Read more


Investigators create ‘Trojan Horse’ to fight Ebola

Sep. 8, 2016—A multi-center research team including scientists from the Vanderbilt Vaccine Center has come up with a clever “Trojan Horse” strategy for thwarting the highly lethal Ebola virus.

Read more


Research team takes aim at Ebola virus ‘decoy protein’

Aug. 11, 2016—Using an antibody generated at Vanderbilt University Medical Center that neutralizes the Ebola virus, researchers at the Scripps Research Institute in La Jolla, California, have determined the structure of a “decoy” protein that may enable the virus to evade detection by the immune system.

Read more


Vanderbilt and Human Vaccines Project launch initial studies to decode the human immune system

Jun. 21, 2016—Researchers at Vanderbilt University Medical Center this month began recruiting volunteers to participate in a clinical trial aimed at decoding the human “immunome,” the genetic underpinnings of the immune system.

Read more


Potent HIV antibodies suggest new vaccine development approach

Apr. 7, 2016—It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks.

Read more


Vanderbilt researchers identify potential antibody treatment for H7 avian flu

Mar. 7, 2016—Researchers at Vanderbilt University Medical Center have isolated human antibodies against a type of bird flu that has killed more than 200 people in China since 2012 and which may pose a worldwide pandemic threat.

Read more


Antibodies may be ‘silver bullet’ for Ebola viruses

Jan. 21, 2016—There may be a “silver bullet” for Ebola, a family of hemorrhagic viruses, one of which has killed more than 11,000 people in West Africa in the past two years.

Read more


VIEW MORE EVENTS >